胰岛素治疗囊性纤维化儿童早期血糖异常:CF-IDEA随机对照试验
CF-IDEA多中心随机对照试验纳入5-18岁无囊性纤维化相关糖尿病但OGTT显示早期血糖异常的囊性纤维化儿童,比较每日长效胰岛素detemir与观察对体重Z评分和肺功能的影响。结果显示胰岛素组与观察组在体重Z评分、ppFEV1和ppFVC变化上均无显著差异,且无严重低血糖或胰岛素相关不良事件。结论不支持对未达OGTT糖尿病诊断标准的患儿使用胰岛素。
要点
- 胰岛素治疗未改善早期血糖异常囊性纤维化患儿的体重Z评分和肺功能。
核心结论
- 对囊性纤维化早期血糖异常但未达囊性纤维化相关糖尿病诊断标准的儿童,胰岛素治疗未改善体重或肺功能。
- 胰岛素治疗不应给予未满足OGTT囊性纤维化相关糖尿病标准的患者。
研究设计与样本
- CF-IDEA为多中心随机对照试验,在澳大利亚五家儿童医院和美国一家儿童医院开展。
- 109例随机分配至观察组(n=54)或胰岛素组(n=55),分析纳入104例(观察53例,胰岛素51例)。
- 主要结局为体重Z评分、ppFEV1和ppFVC的绝对变化,用广义估计方程分析并提供双侧95%CI。
关键数值与推荐
- 严重低血糖定义为需要外部帮助或导致意识水平下降或癫痫发作。
临床怎么用
- 对于囊性纤维化儿童,仅根据OGTT早期血糖异常(未达囊性纤维化相关糖尿病标准)不应启动胰岛素治疗。
- 应继续以OGTT标准诊断囊性纤维化相关糖尿病后再考虑胰岛素治疗。
局限性
- 研究仅纳入5-18岁儿童,结果不能外推至成人或更年幼儿童。
- 部分参与者仅完成6个月方案(9例),可能影响12个月结局的完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with cystic fibrosis can have impaired insulin secretion and hyperglycaemia before meeting the diagnostic criteria for cystic fibrosis-related diabetes during an oral glucose tolerance test (OGTT). Insulin therapy given to such patients was associated with improved weight and lung function in several small, uncontrolled trials but might increase treatment burden and cause hypoglycaemia. We aimed to assess whether insulin treatment improves weight and lung function when given to patients with cystic fibrosis with early glycaemic abnormality. METHODS: CF-IDEA was a multicentre, randomised controlled trial conducted at five children's hospitals in Australia and one in the USA. Eligible participants were children with cystic fibrosis aged 5-18 years without cystic fibrosis-related diabetes and with peak glucose concentration on a five-point OGTT of 8·2-11·0 mmol/L (cystic fibrosis insulin deficiency stage 1) or ≥11·1 mmol/L (cystic fibrosis insulin deficiency stage 2). Participants were randomly assigned (1:1) to insulin or observation. Randomisation was done using the biased coin method, followed by minimisation when the study groups became imbalanced by chance. Randomisation was stratified by glycaemic category (cystic fibrosis insulin deficiency stage 1 or 2), weight Z score (more than or equal to -0·61 or less than -0·61), and study centre. Participants in the insulin group received once-daily, long-acting insulin detemir by subcutaneous injection before breakfast, commencing at 0·1 units per kg per day, adjusted in 0·5-unit increments to achieve all fingerstick blood glucose concentrations between 4 mmol/L and 8 mmol/L. The primary outcomes were absolute changes in weight Z score, percentage predicted forced expiratory volume in 1 s (ppFEV1), and percentage predicted forced vital capacity (ppFVC), derived with generalised estimating equations and presented with two-sided 95% CIs. Severe hypoglycaemic events (defined as requiring outside assistance or causing reduced level of consciousness or seizure), insulin-related adverse events, and continuous glucose monitoring (CGM) percentage time with blood glucose below 3·9 mmol/L were recorded as safety outcomes. This study is registered with ClinicalTrials.gov, NCT01100892, and is completed. FINDINGS: Between Dec 6, 2010, and Feb 25, 2022, 109 participants were randomly assigned to observation (n=54) or insulin (n=55). Five participants withdrew after the baseline visit, and the analysis therefore included 104 participants (53 observation and 51 insulin); 95 participants completed the 12-month protocol and nine completed only 6 months. Baseline characteristics were similar between the groups; however, the observation group included 30 (57%) boys and 23 (43%) girls, whereas the insulin group included 23 (45%) boys and 28 (55%) girls. The median daily insulin dose at 12 months was 0·12 units per kg per day (range 0·05-0·41). There were no statistically or clinically significant differences between the observation and insulin groups in change in weight Z score (difference insulin minus observation 0·07 [95% CI -0·04 to 0·18]; p=0·20), change in ppFEV1 (1·2 [-2·2 to 4·7]; p=0·48), or change in ppFVC (0·6 [-2·6 to 3·8]; p=0·72). Similarly, there were no significant differences in subgroup analyses by cystic fibrosis insulin deficiency stages 1 and 2. There were no episodes of severe hypoglycaemia or insulin-related adverse events, and we found no evidence of difference between the observation and insulin groups in CGM percentage time less than 3·9 mmol/L. INTERPRETATION: Insulin treatment did not improve weight or lung function when given to children and adolescents with cystic fibrosis and early glycaemic abnormalities. Insulin treatment should not be given to those who do not meet OGTT criteria for cystic fibrosis-related diabetes. FUNDING: National Health and Medical Research Council of Australia, Australian Cystic Fibrosis Research Trust, Pfizer Australasian Paediatric Endocrine Care Research Grant, Novo Nordisk Regional Diabetes Support Scheme, Sydney Children's Hospital Foundation.
引用
- Hameed S, Barnes EH, Briody J, et al. Insulin for early glycaemic abnormality in children with cystic fibrosis without cystic fibrosis-related diabetes (CF-IDEA): a randomised controlled trial. Lancet Child Adolesc Health. 2025. PMID: 40379429. doi:10.1016/S2352-4642(25)00099-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。